Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis

@article{Leucht2012AntipsychoticDV,
  title={Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis},
  author={Stefan Leucht and Magdolna Tardy and Katja Komossa and Stephan Heres and Werner Kissling and Georgia Salanti and John M. Davis},
  journal={The Lancet},
  year={2012},
  volume={379},
  pages={2063-2071}
}

Figures from this paper

Examination of Dosing of Antipsychotic Drugs for Relapse Prevention in Patients With Stable Schizophrenia: A Meta-analysis.
TLDR
The findings of this meta-analysis suggest that doses higher than approximately 5-mg/d risperidone equivalent may provide limited additional benefit for relapse prevention but more adverse events.
Benefits and harms of antipsychotic drugs in drug-naïve patients with psychosis: A systematic review
TLDR
Withdrawal effects in the placebo groups make existing placebo-controlled trials unreliable and the use of antipsychotics cannot be justified based on the evidence the authors currently have.
Psychosocial treatments for relapse prevention in schizophrenia: study protocol for a systematic review and network meta-analysis of randomised evidence
TLDR
A network meta-analysis is conducted, integrating direct and indirect comparisons from randomised controlled trials (RCTs) to rank psychosocial treatments for relapse prevention in schizophrenia according to their efficacy, acceptability and tolerability, to obtain a comprehensive ranking of all treatments.
Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy Predictors.
TLDR
Almost twice as many patients improved with antipsychotics as with placebo, but only a minority experienced a good response, and drug development may benefit from smaller samples but better-selected patients.
Factors associated with successful antipsychotic dose reduction in schizophrenia: a systematic review of prospective clinical trials and meta-analysis of randomized controlled trials
TLDR
Clinicians should consider the long-term risk of relapse in younger patients with a relatively short illness duration and keep the final doses higher than CPZE 200 mg/day when reducing antipsychotic doses.
Benefits and harms of antipsychotic drugs in drug-naı̈ve patients with psychosis: A systematic review
TLDR
Withdrawal effects in the placebo groups make existing placebo-controlled trials unreliable and the use of antipsychotics cannot be justified based on the evidence the authors currently have.
Long-acting atypical antipsychotics in schizophrenia: A systematic review and meta-analyses of effects on functional outcome
TLDR
Long-acting injectable atypical antipsychotics are beneficial for recovery of psychosocial function in comparison with placebo, but the magnitude of superiority over oral antipsychotic treatment was small.
...
...

References

SHOWING 1-10 OF 52 REFERENCES
Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.
TLDR
Overall, the currently available data suggest that new-generation antipsychotic drugs have the potential to reduce relapse rates.
Maintenance treatment with antipsychotic drugs for schizophrenia.
TLDR
The efficacy of antipsychotic drugs for maintenance treatment in schizophrenia was clear and the results of the primary outcome were robust in a number of subgroup, meta-regression and analyses.
Antipsychotic prophylaxis is needed after remission from a first psychotic episode in schizophrenia patients: Results from an aborted randomised trial
TLDR
Discontinuation of antipsychotic medication markedly increases the risk of relapse in stable remitted first-episode schizophrenia patients.
Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study.
TLDR
Aripiprazole, 15 mg once daily, is an effective, well-tolerated treatment for prevention of relapse in patients with chronic, stable schizophrenia.
Zotepine in the prevention of recurrence: a randomised, double-blind, placebo-controlled study for chronic schizophrenia
TLDR
Zotepine is effective in preventing recurrence in patients with chronic schizophrenia, and scores on the BPRS and CGI supported the efficacy of zotEPine.
Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial
TLDR
In a group of asymptomatic patients with first episode psychosis and at least one year of previous antipsychotic drug treatment, maintenance treatment with quetiapine compared with placebo resulted in a substantially lower rate of relapse during the following year.
Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomized, placebo-controlled trial in clinically stable patients.
TLDR
Once-daily quetiapine XR (400-800mg/day) was effective in preventing relapse in patients with clinically stable schizophrenia and was well tolerated during longer-term use.
A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment.
TLDR
Long-term treatment with asenapine was more effective than placebo in preventing relapse of schizophrenia and appeared to be safe and well tolerated.
...
...